Hemostatic abnormalities in dogs with carcinoma: A thromboelastographic characterization of hypercoagulability

Veterinary Journal

Volumn 190, Issue 2, 2011, Pages

  Vilar Saavedra, Paulo ^a,b   Lara García, Ana ^a,c   Zaldívar López, Sara ^a   Couto, Guillermo ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c ROYAL VETERINARY COLLEGE   (United Kingdom)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer; Dogs; Hemostasis; Hypercoagulability; Thromboelastography

Indexed keywords

ANTITHROMBIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; THROMBOPLASTIN;

ANUS CARCINOMA; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN DEFECT; GASTROINTESTINAL CARCINOMA; HEMOSTASIS; HYPERCOAGULABILITY; HYPERFIBRINOGENEMIA; LIVER CARCINOMA; LUNG CARCINOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL ANALYSIS; NONHUMAN; NOSE CARCINOMA; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOELASTOGRAPHY; THROMBUS; THYROID CARCINOMA; TRANSITIONAL CELL CARCINOMA;

ANIMALS; ANTITHROMBIN III; CASE-CONTROL STUDIES; DOG DISEASES; DOGS; FEMALE; FIBRINOGEN; HEMOSTASIS; HEMOSTATIC DISORDERS; MALE; NEOPLASMS; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBELASTOGRAPHY; THROMBOPHILIA;

CANIS FAMILIARIS;

EID: 82855178860     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2011.02.025     Document Type: Article

References (51)

1. Bergam P.J. Paraneoplastic syndromes. Small Animal Clinical Oncology 2007, 77-94. Saunders and Elsevier, St. Louis, MO, USA. forth ed. S. Withrow, J. MacEwen's (Eds.).
2. Blom J.W., Doggen C.J., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. Journal of the American Medical Association 2005, 293:715-722.
3. Chorostowska-Wynimko J., Skrzypczak-Jankun E., Jankun J. Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis. International Journal of Molecular Medicine 2004, 13:759-766.
4. Cloonan M.E., DiNapoli M., Mousa S.A. Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis. Blood Coagulation and Fibrinolysis 2007, 18:341-345.
5. Donahue A.M., Otto C.M. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis. Journal of Veterinary Emergency and Critical Care 2005, 15:9-16.
6. Dvorak H.F. Thrombosis and cancer. Human Pathology 1987, 18:275-284.
7. Enzygnost TAT Micro 2005-2009. Dade Behring Marburg GmbH, Marburg, Germany, p. 1.
8. Falanga A., Gordon S.G. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985, 24:5558-5567.
9. Falanga A., Rickles F.R. Pathophysiology of the thrombophilic state in the cancer patient. Seminars in Thrombosis and Hemostasis 1999, 2:173-182.
10. Gastl G., Plante M., Finstad C.L., Wong G.Y., Federici M.G., Bander N.H., Rubin S.C. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. British Journal of Haematology 1993, 83:433-441.
11. Gungor T., Kanat-Pektas M., Sucak A., Mollamahmutoglu L. The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Archives of Gynecology and Obstetricy 2009, 279:53-56.
12. Hammer A.S. Thrombocytosis in dogs and cats: a retrospective study. Comparative Hematology International. 1991, 1:181-186.
13. Hoffman M., Monroe D.M. A modern view of hemostasis. Hematology/Oncology Clinics of North America 2007, 21:1-11.
14. Howard A., Liebman N., Ilene Weitz. Disseminated intravascular coagulation. Hematology Basic Principles and Practice 2005, 1224-1263. Elsevier, Philadelphia, PA, USA. 4th ed. H. Ronald, E. Benz, S. Shattil, B. Furie, H. Cohen, L. Silberstein, P. McGlave (Eds.).
15. Kristensen A.T., Wiinberg B., Jessen A.E., Jensen A.L. Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia. Journal of Veterinary Internal Medicine 2008, 22:140-147.
16. Lane D.A., Bowry S.K. The scientific basis for selection of measures of thrombogenecity. Nephrology, Dialysis and Transplantation 1994, 9:18-28.
17. Mannucci P.M. The measurement of multifactorial thrombophilia. Thrombosis and Haemostasis 2002, 88:1-2.
18. Maruyama H., Miura T., Sakai M., Koie H., Yamaya Y., Shibuya H., Sato T., Watari T., Takeuchi A., Tokuriki M., Hasegawa A. The incidence of disseminated intravascular coagulation in dogs with malignant tumor. Journal of Veterinary Medicine Science 2004, 66:573-575.
19. Maruyama H., Watari T., Miura T., Sakai M., Takahashi T., Koie H., Yamaya Y., Asano K., Edamura K., Sato T., Tanaka S., Hasegawa A., Tokuriki M. Plasma thrombin-antithrombin complex concentrations in dogs with malignant tumours. Veterinary Record 2005, 156:839-840.
20. McMahon G.A., Petitclerc E., Stefansson S., Smith E., Wong M.K., Westrick R.J., Ginsburg D., Brooks P.C., Lawrence D.A. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. Journal of Biological Chemistry 2001, 276:33964-33968.
21. Mischke R., Wohlsein P., Busse L., Pohlenz J. Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma. Schweizer Archiv für Tierheilkunde 1998, 140:497-505.
22. Morales F., Couto C.G., Iazbik M.C. Effects of two concentrations of sodium citrate on coagulation test results, von Willebrand factor concentration, and platelet function in dogs. Journal of Veterinary Internal Medicine 2007, 21:472-475.
23. Nekarda H., Siewert J.R., Schmitt M., Ulm K. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994, 343:117.
24. O'Donnell M.R., Slichter S.J., Weiden P.L., Storb R. Platelet and fibrinogen kinetics in canine tumors. Cancer Research 1981, 41:1379-1383.
25. Otto C.M., Rieser T.M., Brooks M.B., Russell M.W. Evidence of hypercoagulability in dogs with parvoviral enteritis. Journal of the American Veterinary Medical Association 2000, 217:1500-1504.
26. Papa M.L., Capasso F., Pudore L., Torre S., Mango S., Russo V., Delrio P., Palaia R., Ruffolo F., d'Eufemia M.D., De Lucia D., Napolitano M., Di Micco P., Parisi V. Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer. Experimental Oncology 2007, 29:111-115.
27. Pedersen H., Nils Brünner N., Francis D., Osterlind K., Rønne E., Hansen H.H., Danø K., Grøndahl-Hansen J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Research 1994, 54:4671-4675.
28. Peterson H.I., Kjartansson I., Korsan-Bengtsen K., Rudenstam C.M., Zettergren L. Fibrinolysis in human malignant tumours. Acta Chirurgica Scandinavica 1973, 139:219-223.
29. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncology 2005, 6:401-410.
30. Rivard G.E., Brummel-Ziedins K.E., Mann K.G., Fan L., Hofer A., Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. Journal of Thrombosis and Haemostasis 2005, 3:2039-2043.
31. Salgado R., Vermeulen P.B., Benoy I., Weytjens R., Huget P., Van Marck E., Dirix L.Y. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. British Journal of Cancer 1999, 80:892-897.
32. Sierko E., Wojtukiewicz M.Z. Platelets and angiogenesis in malignancy. Seminars in Thrombosis and Hemostasis 2004, 30:95-108.
33. Spectrolyse/pL PAI Catalogue 101201, 2006. Trinity Biotech plc, Bray, Wicklow, Ireland, p. 1.
34. Stefansson S., Petitclerc E., Wong M.K., McMahon G.A., Brooks P.C., Lawrence D.A. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. Journal of Biological Chemistry 2001, 16:8135-8141.
35. Stockhaus C., Kohn B., Rudolph R., Brunnberg L., Giger U. Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma. Journal of Small Animal Practice 1999, 40:326-331.
36. Symbas N.P., Townsend M.F., El-Galley R., Keane T.E., Graham S.D., Petros J.A. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU International 2000, 86:203-207.
37. Tarnow I., Falk T., Tidholm A., Martinussen T., Jensen A.L., Olsen L.H., Pedersen H.D., Kristensen A.T. Hemostatic biomarkers in dogs with chronic congestive heart failure. Journal of Veterinary Internal Medicine 2007, 21:451-457.
38. TEG 5000 User's Manual Haemoscope, 1995-2005, Niles, IL. Version 4.2 Software, pp. 4-11.
39. Tvedten H. The complete blood count and bone marrow examination. General comments and selected techniques. Small Animal Diagnosis by Laboratory Methods 1994, 11-30. W.B. Saunders, Philadelphia, PA. second ed. M.D. Willard, H. Tvedten, G.H. Turnwald (Eds.).
40. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007, 15:1723-1729.
41. Vilar P., Couto C.G., Westendorf N., Iazbik C., Charske J., Marín L. Thromboelastographic tracings in retired racing greyhounds and in non-greyhound dogs. Journal of Veterinary Internal Medicine 2008, 22:374-379.
42. Wada H., Sase T., Yamaguchi M. Hypercoagulant states in malignant lymphoma. Experimental Oncology 2005, l27:179-185.
43. Wiinberg B., Jensen A.L., Rojkjaer R., Johansson P., Kjelgaard-Hansen M., Kristensen A.T. Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs. Veterinary Clinical Pathology 2005, 34:389-393.
44. Wiinberg B., Jensen A.L., Johansson P.I., Rozanski E., Tranholm M., Kristensen A.T. Thromboelastographic evaluation of hemostatic function in dogs with disseminated intravascular coagulation. Journal of Veterinary Internal Medicine 2008, 22:357-365.
45. Wiinberg B., Jensen A.L., Rozanski E., Johansson P.I., Kjelgaard-Hansen M., Tranholm M., Kristensen A.T. Tissue factor activated thromboelastography correlates to clinical signs of bleeding in dogs. The Veterinary Journal 2009, 179:121-129.
46. Wojtukiewicz M.Z., Tang D.G., Nelson K.K., Walz D.A., Diglio C.A., Honn K.V. Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thrombosis Research 1992, 68:233-245.
47. Wojtukiewicz M.Z., Tang D.G., Ciarelli J.J., Nelson K.K., Walz D.A., Diglio C.A., Mammen E.F., Honn K.V. Thrombin increases the metastatic potential of tumor cells. International Journal of Cancer 1993, 54:793-806.
48. Wojtukiewicz M.Z., Sierko E., Klement P., Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001, 3:371-384.
49. Wojtukiewicz M.Z., Sierko E., Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Seminars in Thrombosis and Hemostasis 2004, 30:5-20.
50. Wojtukiewicz M.Z., Sierko E., Kisiel W. The role of hemostatic system inhibitors in malignancy. Seminars in Thrombosis and Hemostasis 2007, 33:621-642.
51. Wolberg A.S., Campbell R.A. Thrombin generation, fibrin clot formation and hemostasis. Transfusion and Apheresis Science 2008, 38:15-23.